Search clinical trials for: Transplant not eligible

Total 30000 results

David Bond, MD

Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Nantes University Hospital

Recruiting

Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation (ILDA)

Acute Myeloid Leukemia (AML)

France
University of Leeds
Takeda; Cancer Research UK; Celgene

Recruiting

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)

Multiple Myeloma

United Kingdom
Sanofi

Active, not recruiting

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

Plasma Cell Myeloma

Mexico, Sweden, Poland, France, Czechia, Greece, Taiwan, Lithuania, Portugal, Spain, Australia, Italy, New Zealand, Russian Federation, Turkey, Japan, United States, Belgium, China, Denmark, Germany
Celgene

Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD)

Lymphoma, Non-Hodgkin

Italy, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Seagen Inc.

Terminated

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, (CheckMate 812)

Hodgkin's Disease

United States, Japan, Puerto Rico
Ciceri Fabio

Completed

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (FLAT-Auto)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Transplant-Related Hematologic Malignancy

Italy
Sumitomo Pharma America, Inc.

Terminated

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Myelodysplastic Syndromes (MDS)

United States
Fondazione EMN Italy Onlus

Active, not recruiting

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (KRdvsRd)

Multiple Myeloma | New Diagnosis Tumor

Italy
Northside Hospital, Inc.
Merck Sharp & Dohme LLC

Completed

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Acute Myeloid Leukemia

United States
University of California, San Francisco
Oregon Health and Science University

Completed

Deceased Organ Donor Interventions to Protect Kidney Graft Function

Brain Death | Organ Donation | Delayed Graft Function | Organ Transplant Failure or Rejection

United States
Celgene

Active, not recruiting

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Multiple Myeloma

Netherlands, Belgium, Denmark, Germany, United Kingdom, France, Norway, Spain, Austria, Ireland, Italy, Sweden
University Hospital, Toulouse
Ministry of Health, France; Janssen, LP

Completed

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma (IFM2014-02)

Multiple Myeloma

France, Belgium
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
Bristol-Myers Squibb

Completed

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Lymphoma. Non-Hodgkin

Germany, Italy, United States, Spain, Netherlands, Australia, United Kingdom, Belgium, France, Canada, Sweden, Singapore
University Health Network, Toronto

Withdrawn

Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI) (RADBRI)

Hepatocellular Carcinoma
Samsung Medical Center
Seok Jin Kim

Terminated

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma (ZOLINZA)

Mantle Cell Lymphoma

Korea, Republic of
Cigdem Sahinbas YILMAZ
Turkish Society of Hematology Myeloma Study Group

Completed

Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma

Multiple Myeloma

Turkey
Shenzhen Zhongxing Yangfan Biotech Co. Ltd.
The 12th Guangzhou Municipal Hospital; Liu Hua Qiao Hospital

Unknown

Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia

Anemia, Aplastic

China
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Acquired Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Acquired Amegakaryocytic Thrombocytopenia
University Hospital, Angers

Not yet recruiting

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. (ALHERT)

Lymphoma | Leukemia | Multiple Myeloma

France
Hospital Sirio-Libanes
Daiichi Sankyo

Not yet recruiting

Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE (VISIONAIRE) (VISIONAIRE)

Chronic Kidney Diseases | Atrium; Fibrillation
Virginia Commonwealth University

Not yet recruiting

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality (REMAIN1)

Acute Myeloid Leukemia

United States
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; CGenetix

Not yet recruiting

Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection (DART-RREGREF)

Kidney Transplant Patients Eligible for a Solid Biopsy
I.M. Sechenov First Moscow State Medical University

Recruiting

Collagen for Treatment of Musculoskeletal Injuries

Anterior Cruciate Ligament Injuries | Hallux Rigidus

Russian Federation
Senti Biosciences

Recruiting

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

AML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies

United States, Australia
Rigshospitalet, Denmark

Recruiting

Intraoperative Intestinal Perfusion Assessment by Fluorescence Angiography in Emergency Surgery

Bowel; Ischemic, Acute

Denmark
Arpan A. Patel, MD

Recruiting

CM for Patients With ALD After Liver Transplant

Contingency Management | Alcohol Use Disorder | Post Liver Transplant | Alcohol; Liver | Alcohol Liver Disease

United States
Incyte Biosciences Italy S.r.l
Advice Pharma Group srl

Recruiting

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

DLBCL - Diffuse Large B Cell Lymphoma

Italy
Wuhan Union Hospital, China

Not yet recruiting

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Myelodysplastic Syndromes
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; Nottingham Trent University; Sheffield Hospitals Charity

Recruiting

Biomarkers of aHSCT (BIO-MS)

Multiple Sclerosis, Relapsing-Remitting

United Kingdom
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
University Hospital, Strasbourg, France

Recruiting

Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab (m-TMA)

Thrombotic Microangiopathies

France
Hoffmann-La Roche

Recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Large B-Cell Lymphoma

Belgium, Korea, Republic of, Australia, China, Japan, United States, Italy, Spain, Taiwan, United Kingdom, France, Mexico, Poland, Germany, Turkey, Brazil, Argentina, Denmark, Canada
Colorado Prevention Center
Bayer; Saint Luke's Hospital of Kansas City

Not yet recruiting

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)

Heart Failure
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Brazil, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia, Belgium
Pfizer
Merck Sharpe & Dohme LLC

Recruiting

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Melanoma

Italy, Spain, Czechia, Germany, Slovakia, Poland, United Kingdom
Nantes University Hospital

Recruiting

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT (FLUCLORIC)

Acute Myeloid Leukemia in Remission

France
Centre hospitalier de l'Université de Montréal...
Canadian Institutes of Health Research (CIHR)

Recruiting

Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users

Addiction | Methamphetamine-dependence | Addiction, Substance | Methamphetamine Abuse

Canada
University of Leipzig
AbbVie; University Hospital Leipzig, Hematology Diagnostics Laboratory; University...

Recruiting

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

Acute Myeloid Leukemia (AML)

Germany
Regeneron Pharmaceuticals

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

Multiple Myeloma

United States, France
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Conditioning | Haploidentical Stem Cell Transplantation

China
Hoffmann-La Roche

Recruiting

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

Korea, Republic of, United States, China, Spain, Germany, France, United Kingdom, Poland, Australia
University Hospital Heidelberg
AstraZeneca

Recruiting

Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients With Acute Coronary Syndrome in a Real-world Registry (AZ-DAPT)

Acute Myocardial Infarction

Germany
Rima Rachid
University of Minnesota

Recruiting

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Peanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, Peanut

United States
Medical University of Gdansk

Recruiting

NPWT vs Primary Closure in SSI Prevention for Emergency Laparotomies for Peritonitis (PRISTINE)

Infections | Surgical Site Infection | Wound Infection | Peritonitis

Poland
Johns Hopkins University

Recruiting

Uterus Transplantation to Treat Infertility (OPRTUNTI)

Uterine Factor Infertility

United States
Medical University of Gdansk

Not yet recruiting

Continuous Glucose Monitoring for Emergency Laparotomy (CLUE)

Hyperglycemia | Infections | Hypoglycemia | Surgical Site Infection | Peritonitis

Poland
Pfizer

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)

Multiple Myeloma

Japan, Taiwan, Canada, Spain, Australia, Italy, Czechia, Korea, Republic of, France, Greece, Israel, Poland, Germany

Search clinical trials for: Transplant not eligible

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations